跳至主要内容
临床试验/NCT01983644
NCT01983644已完成不适用

RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study: a Prospective Randomised Control Trial(REDIRECT)

Jinling Hospital, China10 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2013年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
130
试验地点
10
主要终点
Revascularization Status

研究概览

简要总结

Endovascular therapy is increasingly used for patients with moderate-to-severe acute ischemic stroke.This study will compare the efficacy and safety of RECO(a novel, self-expanding stent retriever) with Solitaire FR within 8 hours of stroke onset caused by the large vessel occlusion.

详细描述

RECO is a novel, self-expanding stent retriever, designed to yield rapid flow restoration in acute cerebral ischaemia. The proposed study is a multicenter, randomized, prospective, parallel-group, open-label clinical trial with a blinded outcome, to test the RECO(a novel, self-expanding stent retriever), as compared with Solitaire FR stent retriever.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age (18-80 years)
  • acute ischemic stroke
  • within 8 hours after symptom onset
  • a large-vessel confirmed by CTA/MRA (eg, internal carotid, middle cerebral M1 and/or M2 segments)
  • NIHSS(≥8 and ≤24)
  • patients or their legally authorised representatives provided signed, informed consent.

排除标准

  • CT or MRI evidence of intracranial haemorrhage/tumor
  • major ischaemic infarction (acute ischaemic change in more than a third of the middle cerebral artery territory)
  • NIHSS(≥25 and ≤7)
  • severe sustained hypertension (systolic blood pressure >185 mm Hg or diastolic blood pressure >110 mm Hg)
  • baseline glucose concentrations of less than 2·7 mmol/L or higher than 21.6 mmol/L
  • known haemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with an international normalised ratio of more than 1.7
  • treatment with heparin within 48 h with a partial thromboplastin time more than two times the laboratory normal, baseline platelet count of less than 100×10^9/L
  • history of severe allergy (worse than rash) to contrast medium or nitinol

研究组 & 干预措施

RECO thrombectomy

Experimental

IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.

干预措施: RECO flow restoration device (Device)

Solitaire FR thrombectomy

Active Comparator

IA thrombectomy is executed by Solitaire FR flow restoration device

干预措施: Solitaire FR flow restoration device (Device)

结局指标

主要结局

Revascularization Status

时间窗: Post-procedure, immediate=at the end of the procedure, per last angiogram during treatment

Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure Thrombolysis in Cerebral Infarction (TICI) grading system for perfusion (ie blood flow through a vessel) Grade 0:No Perfusion. No antegrade flow beyond the point of occlusion. Grade 1:Penetration With Minimal Perfusion. Grade 2:Partial Perfusion. Grade 2a:Only partial filling (\<2/3) of the entire vascular territory is visualized. Grade 2b:Complete filling of all of the expected vascular territory is visualized, but slower . Grade 3:Complete Perfusion.

次要结局

  • Clinical Outcomes at 90 Days(90-day)
  • all-cause mortality at 90 days(procedure through 90 days)
  • intracranial hemorrhages(24 hours)

研究者

发起方
Jinling Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xinfeng Liu

Professor

Jinling Hospital, China

研究点 (10)

Loading locations...

相似试验

RECO Flow Restoration Device Versus Solitaire FR... | 临床试验